JPWO2022026914A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022026914A5 JPWO2022026914A5 JP2023506315A JP2023506315A JPWO2022026914A5 JP WO2022026914 A5 JPWO2022026914 A5 JP WO2022026914A5 JP 2023506315 A JP2023506315 A JP 2023506315A JP 2023506315 A JP2023506315 A JP 2023506315A JP WO2022026914 A5 JPWO2022026914 A5 JP WO2022026914A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- seq
- histidine
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059502P | 2020-07-31 | 2020-07-31 | |
| US63/059,502 | 2020-07-31 | ||
| PCT/US2021/044043 WO2022026914A1 (en) | 2020-07-31 | 2021-07-30 | Anti-connexin antibody formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537316A JP2023537316A (ja) | 2023-08-31 |
| JPWO2022026914A5 true JPWO2022026914A5 (https=) | 2024-08-07 |
| JP2023537316A5 JP2023537316A5 (https=) | 2024-08-07 |
Family
ID=80002768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506315A Pending JP2023537316A (ja) | 2020-07-31 | 2021-07-30 | 抗コネキシン抗体製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11912764B2 (https=) |
| EP (1) | EP4188544A4 (https=) |
| JP (1) | JP2023537316A (https=) |
| KR (1) | KR20230042744A (https=) |
| CN (1) | CN116234576A (https=) |
| AU (1) | AU2021316119A1 (https=) |
| CA (1) | CA3190474A1 (https=) |
| IL (1) | IL300245A (https=) |
| WO (1) | WO2022026914A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095897A1 (en) * | 2018-04-02 | 2019-10-10 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| WO2022026914A1 (en) | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| US20250277017A1 (en) * | 2022-04-29 | 2025-09-04 | Board Of Regents, The University Of Texas System | Compositions and methods for treating eye diseases |
| WO2025006774A1 (en) * | 2023-06-30 | 2025-01-02 | Alamab Therapeutics, Inc. | Method of treating osteoarthritis |
| WO2025038635A1 (en) * | 2023-08-14 | 2025-02-20 | Alamab Therapeutics, Inc. | Method of treating stroke |
| US20260103512A1 (en) * | 2024-05-24 | 2026-04-16 | Alamab Therapeutics, Inc. | Method of treating bone cancers |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102073629B1 (ko) | 2005-02-03 | 2020-02-05 | 코다 테라퓨틱스 (엔지) 리미티드 | 항-코넥신 화합물 및 그의 용도 |
| EP1871806A2 (en) * | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
| US20110223204A1 (en) | 2008-06-04 | 2011-09-15 | Bradford J Duft | Treatment of pain with gap junction modulation compounds |
| MX2011009312A (es) * | 2009-03-06 | 2012-02-29 | Medimmune Llc | Formulaciones de anticuerpos humanizados anti-cd19. |
| CA2823154A1 (en) | 2010-12-27 | 2012-07-05 | Lsip, Llc | Ips cells and method for generating same |
| CN114621346B (zh) | 2013-08-21 | 2025-06-10 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| CN107109410B (zh) | 2014-08-22 | 2021-11-02 | 奥克兰联合服务有限公司 | 通道调节剂 |
| US20190010224A1 (en) * | 2015-12-22 | 2019-01-10 | Merck Sharp & Dohme Corp. | Formulations of engineered anti-il-10 antibodies |
| EP3419599A4 (en) * | 2016-02-23 | 2019-09-11 | Sesen Bio, Inc. | IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF |
| WO2017147561A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF |
| WO2017190152A1 (en) | 2016-04-29 | 2017-11-02 | Ocunexus Therapeutics, Inc. | Sustained release drug delivery devices |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP2020531523A (ja) * | 2017-08-25 | 2020-11-05 | オメロス コーポレーション | 高度に濃縮された低粘度のｍａｓｐ−２阻害抗体製剤、キット、および非定型溶血性症候群に罹患した対象の治療方法 |
| CA3095897A1 (en) | 2018-04-02 | 2019-10-10 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| US11274150B2 (en) * | 2018-11-16 | 2022-03-15 | Bristol-Myers Squibb Company | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
| AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| KR20220113355A (ko) * | 2019-10-02 | 2022-08-12 | 알라맵 테라퓨틱스, 인크. | 항-코넥신 항체 제제 |
| WO2022026914A1 (en) | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
-
2021
- 2021-07-30 WO PCT/US2021/044043 patent/WO2022026914A1/en not_active Ceased
- 2021-07-30 IL IL300245A patent/IL300245A/en unknown
- 2021-07-30 CN CN202180062049.8A patent/CN116234576A/zh active Pending
- 2021-07-30 EP EP21851080.8A patent/EP4188544A4/en active Pending
- 2021-07-30 CA CA3190474A patent/CA3190474A1/en active Pending
- 2021-07-30 AU AU2021316119A patent/AU2021316119A1/en active Pending
- 2021-07-30 KR KR1020237006832A patent/KR20230042744A/ko active Pending
- 2021-07-30 US US17/390,635 patent/US11912764B2/en active Active
- 2021-07-30 JP JP2023506315A patent/JP2023537316A/ja active Pending
-
2024
- 2024-01-17 US US18/415,511 patent/US20240309085A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6836500B2 (ja) | 自己免疫状態および炎症状態を治療するための方法および組成物 | |
| ES2349779T3 (es) | Formulaciones de anticuerpos y de proteínas a concentración elevada. | |
| JP2026004397A (ja) | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 | |
| AU2021240216A1 (en) | Formulations of monoclonal antibodies | |
| JP7627255B2 (ja) | バイオフィルムを破壊するための抗体組成物 | |
| TW201307390A (zh) | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 | |
| CN107849133A (zh) | 抗cd166抗体、可活化抗cd166抗体及其使用方法 | |
| EA028574B1 (ru) | Способ лечения b-клеточных злокачественных новообразований, экспрессирующих cd19 | |
| KR20150033620A (ko) | 항-pdgf 압타머 및 vegf 길항제를 포함하는 조성물 | |
| JPWO2019157340A5 (https=) | ||
| CN110354073B (zh) | 一种免疫抑制剂单克隆抗体的液体制剂 | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| JP6949916B2 (ja) | 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用 | |
| WO2018121578A1 (zh) | 稳定的包含cd147单克隆抗体的药物制剂 | |
| JPWO2022026914A5 (https=) | ||
| US20060246060A1 (en) | Novel stable formulation | |
| EA200501131A1 (ru) | Парентеральные композиции пептидов для лечения системной красной волчанки | |
| CA3246175A1 (en) | GLAUCOMA TREATMENT METHODS | |
| WO2010075891A1 (en) | Fibcd1 for the prevention and treatment of diseases | |
| US20110038871A1 (en) | Ccr2 inhibitors for treating conditions of the eye | |
| JPWO2021067775A5 (https=) | ||
| JPWO2022178159A5 (https=) | ||
| KR20180123559A (ko) | PEG화 항인간 NGF 항체 Fab' 프래그먼트 함유 의약 조성물 | |
| KR20240134320A (ko) | 소량의 시트르산에 의한 단백질 제제 내 폴리소르베이트 분해 감소 | |
| ES2907222T3 (es) | Método para preparar hiper-inmunoglobulina anti-neumocócica |